<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866385</url>
  </required_header>
  <id_info>
    <org_study_id>D1320C00011</org_study_id>
    <secondary_id>Pharmaceutical Profiles PL1168</secondary_id>
    <nct_id>NCT00866385</nct_id>
  </id_info>
  <brief_title>AZD8566 Food Effect/Microtracer Study</brief_title>
  <official_title>An Open, Randomised, Phase I, 2-Period Crossover Trial to Investigate the Absolute Bioavailability and the Effect of Food on the Oral Bioavailability of AZD8566 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study designed to look at how the drug AZD8566 is taken up by the body when given with or
      without food. In some subjects a comparison will be made with a very small labelled microdose
      given into a vein.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile: concentration of AZD8566 in blood in the presence or absence of food</measure>
    <time_frame>Samples taken during visit 2 and visit 3, at up to 16 defined timepoints pre and post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AZD8566 in healthy volunteers in the fed and fasted state by assessment of vital signs, laboratory variables, ECGs and adverse events</measure>
    <time_frame>Assessments taken during visit 1 and at defined timepoints pre and post dose during visits 2 and 3. Volunteers will be monitored throughout the study for adverse events.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioavailability of an oral solution formulation of AZD8566 in the fasted state compared with an intravenous carbon-14 microtracer dose</measure>
    <time_frame>Samples taken during visit 2, at up to 40 defined timepoints pre and post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intravenous pharmacokinetics</measure>
    <time_frame>Samples taken during visit 2, at up to 40 defined timepoints pre and post dose</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8566</intervention_name>
    <description>Single 6 mg oral solution dose</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8566 IV carbon labelled</intervention_name>
    <description>Single 10 mcg intravenous carbon-14 microtracer dose</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent

          -  Clinically normal physical findings and laboratory values as judged by the
             investigator with normal ECG

          -  Females who are permanently or surgically sterile or post-menopausal and males

        Exclusion Criteria:

          -  History of any convulsions or seizures

          -  History of infection or risk of infection due to recent surgery or trauma

          -  History or presence of conditions know to interfere with the absorption, distribution,
             metabolism and excretion of the study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jo Collier, Dr ,MB, ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmaceutical Profiles, Mere Way, Ruddington Fields, Nottingham NG11 6JS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <last_update_submitted>June 8, 2009</last_update_submitted>
  <last_update_submitted_qc>June 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>H Parmar MD, (Acting) Medical Science Director, Respiratory and</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Healthy Volunteer</keyword>
  <keyword>AZD8566</keyword>
  <keyword>Food Effect</keyword>
  <keyword>Microtracer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

